Jiangsu Hengrui Medicine Co Ltd
Research Jiangsu Hengrui Medicine Co Ltd (600276.SS) on Bullrun: market cap CNY 320.11B, dividend yield 0.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker600276.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCNY
- Market capCNY 320.11B
- Dividend yield0.4%
- Financial periodQ2 2026
- RevenueCNY 7.32B
- Net incomeCNY 2.18B
- Free cash flowCNY 327.87M
- Gross margin86.0%
Valuation Snapshot
latest market cap is CNY 320.11B; dividend yield is 0.4%.
Peer valuation comparison
Latest dividend yield is 0.41% versus a Healthcare sector median of 2.4% (82.9% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 320.11B | n/a | n/a | n/a |
Dividend history
Latest trailing dividend snapshot: yield 0.4%.
About Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
ETFs that hold Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Medicine Co Ltd is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| Franklin MSCI China Paris Aligned Climate UCITS ETF USD Acc | 2.23% | 0.22% |
US-listed ETFs
Jiangsu Hengrui Medicine Co Ltd is held by 62 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares MSCI Emerging Markets ETF (EEM) | 0.02% | 0.72% |
| iShares Core MSCI Emerging Markets ETF (IEMG) | 0.02% | 0.09% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | 0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | 0.03% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| iShares MSCI ACWI ETF (ACWI) | <0.01% | 0.32% |
| iShares MSCI ACWI ex U.S. ETF (ACWX) | 0.01% | 0.32% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | 0.01% | 0.04% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Jiangsu Hengrui Medicine Co Ltd's market cap?
Jiangsu Hengrui Medicine Co Ltd's market capitalization is CNY 320.11B.
Does Jiangsu Hengrui Medicine Co Ltd pay a dividend?
Jiangsu Hengrui Medicine Co Ltd has a dividend yield of 0.4%.
What does Jiangsu Hengrui Medicine Co Ltd do?
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.